Nautilus Biotechnology, Inc. reported the quarter ended March 31, 2026 results: net income $14.7 million.
“Net loss was $14.7 million for the first quarter of 2026”
Nautilus Biotechnology, Inc. — fact timeline
Source-grounded facts extracted from Nautilus Biotechnology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Matthew McIlwain departed as Director at Nautilus Biotechnology, Inc..
“Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting”
Michael Altman departed as Director at Nautilus Biotechnology, Inc..
“each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors”
Vijay Pande departed as Director at Nautilus Biotechnology, Inc..
“each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors”
Michael Altman departed as Director at Nautilus Biotechnology, Inc..
“On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.”
Vijay Pande departed as Director at Nautilus Biotechnology, Inc..
“On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.”
Nautilus Biotechnology, Inc. reported the first quarter ended March 31, 2024 results: net income $18.7 million.
“Net loss was $18.7 million for the first quarter of 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.